Evidence map›Paper›PMID 42582039›Full record

ArticleExploration of targeted anti-tumor therapy2026

Safety and efficacy of delivering systemic treatments concomitantly with whole-brain radiotherapy: a prospective, observational, single-institution study.

Maria Protopapa, Kalliopi Platoni, Michalis Psarras, Styliani-Theonymfi Nikoloudi, Zoi Liakouli, Despoina Alexiou, Christina Armpilia, Christos Antypas, Christos Papadimitriou, Vasileios Kouloulias and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Exploration of targeted anti-tumor therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Maria ProtopapaRadiation Oncology and Stereotactic Radiosurgery Center, Mediterraneo Hospital, 116 75 Glyfada, Greece.ORCID https://orcid.org/0000-0001-6135-1136
Kalliopi PlatoniDepartment of Applied Medical Physics, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, 124 62 Athens, Greece.
Michalis PsarrasRadiation Oncology and Stereotactic Radiosurgery Center, Mediterraneo Hospital, 116 75 Glyfada, Greece.
Styliani-Theonymfi NikoloudiRadiation Oncology Unit, Aretaieion Hospital, Medical School, National and Kapodistrian University of Athens, 115 28 Athens, Greece.
Zoi LiakouliRadiation Oncology Unit, Aretaieion Hospital, Medical School, National and Kapodistrian University of Athens, 115 28 Athens, Greece.
Despoina AlexiouRadiation Oncology and Stereotactic Radiosurgery Center, Mediterraneo Hospital, 116 75 Glyfada, Greece.
Christina ArmpiliaRadiation Oncology Unit, Aretaieion Hospital, Medical School, National and Kapodistrian University of Athens, 115 28 Athens, Greece.
Christos AntypasRadiation Oncology Unit, Aretaieion Hospital, Medical School, National and Kapodistrian University of Athens, 115 28 Athens, Greece.
Christos PapadimitriouOncology Unit, Aretaieion University Hospital, Medical School, National and Kapodistrian University of Athens, 115 28 Athens, Greece.
Vasileios KoulouliasDepartment of Clinical Radiation Oncology, Attikon University Hospital, Medical School, National and Kapodistrian University of Athens, 124 62 Athens, Greece.
Anna ZygogianniRadiation Oncology Unit, Aretaieion Hospital, Medical School, National and Kapodistrian University of Athens, 115 28 Athens, Greece.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Aim: The aim of our study was to evaluate the safety and efficacy of delivering systemic treatments concurrently with whole-brain radiotherapy (WBRT). Methods: A single-institution, prospective observational study was conducted in Athens, Greece, including 99 patients treated with WBRT for brain metastases from September 2017 until October 2019, and with a follow-up period extending to March 2025. The study endpoints included overall survival (OS) for all causes of death, time to intracranial progression (TTICP), and serious acute toxicities. Results: The median OS from all causes of death was 6 months [95% confidence interval (CI): 4.7-7.3]. Concomitant systemic therapy reduced the risk of death ( Conclusions: This study showed that there is no serious toxicity from the combination of systemic therapy with WBRT, and that the OS and the TTICP are not compromised with their concurrent delivery.

Indexed as

brain metastasesconcurrent treatmentsystemic therapywhole-brain radiotherapy (WBRT)

Identifiers

PMID42582039
PMCPMC13456974

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.